These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 20082540)

  • 1. Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.
    Bailey S; Singh A; Azadian R; Huber P; Blum M
    Drug Saf; 2010 Feb; 33(2):139-46. PubMed ID: 20082540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine.
    Martin D; Menschik D; Bryant-Genevier M; Ball R
    Drug Saf; 2013 Jul; 36(7):547-56. PubMed ID: 23657824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An experimental investigation of masking in the US FDA adverse event reporting system database.
    Wang HW; Hochberg AM; Pearson RK; Hauben M
    Drug Saf; 2010 Dec; 33(12):1117-33. PubMed ID: 21077702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
    Trippe ZA; Brendani B; Meier C; Lewis D
    Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
    Beninger P; Murray M
    Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations.
    Sakaeda T; Kadoyama K; Okuno Y
    Int J Med Sci; 2011; 8(6):487-91. PubMed ID: 21897761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions.
    Hauben M; Horn S; Reich L
    Drug Saf; 2007; 30(2):143-55. PubMed ID: 17253879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.
    Kadoyama K; Kuwahara A; Yamamori M; Brown JB; Sakaeda T; Okuno Y
    J Exp Clin Cancer Res; 2011 Oct; 30(1):93. PubMed ID: 21970649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System.
    Hochberg AM; Pearson RK; O'Hara DJ; Reisinger SJ
    Drug Saf; 2009; 32(2):137-46. PubMed ID: 19236120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System.
    Huang J; Meng L; Yang B; Sun S; Luo Z; Chen H
    Sci Rep; 2020 Mar; 10(1):4803. PubMed ID: 32179761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.
    Fang H; Su Z; Wang Y; Miller A; Liu Z; Howard PC; Tong W; Lin SM
    Clin Pharmacol Ther; 2014 May; 95(5):496-8. PubMed ID: 24448476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.
    Kadoyama K; Miki I; Tamura T; Brown JB; Sakaeda T; Okuno Y
    Int J Med Sci; 2012; 9(1):33-9. PubMed ID: 22211087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of stratification on data mining in the US Vaccine Adverse Event Reporting System (VAERS).
    Woo EJ; Ball R; Burwen DR; Braun MM
    Drug Saf; 2008; 31(8):667-74. PubMed ID: 18636785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
    Szarfman A; Machado SG; O'Neill RT
    Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA.
    Fukazawa C; Hinomura Y; Kaneko M; Narukawa M
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1402-1408. PubMed ID: 30324671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.
    Gandhi PK; Gentry WM; Bottorff MB
    Pharmacotherapy; 2012 Oct; 32(10):902-9. PubMed ID: 23033229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AERS spider: an online interactive tool to mine statistical associations in Adverse Event Reporting System.
    Grigoriev I; zu Castell W; Tsvetkov P; Antonov AV
    Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):795-801. PubMed ID: 24677538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS.
    Sakaeda T; Kadoyama K; Yabuuchi H; Niijima S; Seki K; Shiraishi Y; Okuno Y
    Int J Med Sci; 2011; 8(4):332-8. PubMed ID: 21611115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.